China Biologic Products Coverage Initiated at Jefferies Group (CBPO)
Analysts at Jefferies Group began coverage on shares of China Biologic Products (NASDAQ:CBPO) in a research report issued to clients and investors on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $52.00 price target on the stock. Jefferies Group’s target price would indicate a potential upside of 30.26% from the stock’s previous close.
The analysts wrote, “CBPO is a leading fully integrated plasma-based supplier in China. In an industry with high entry barriers and limited competition, CBPO is expected to outgrow the market in the next 5 years, given its solid control of plasma supply, comprehensive product portfolio, robust pipeline, and potential M&A. Initiate coverage with BUY and US$52 PT.”
A number of other firms have also recently commented on CBPO. Analysts at Aegis upgraded shares of China Biologic Products to a “buy” rating in a research note on Monday, March 17th. Analysts at Oppenheimer initiated coverage on shares of China Biologic Products in a research note on Thursday, March 13th. They set an “outperform” rating and a $46.00 price target on the stock.
Shares of China Biologic Products (NASDAQ:CBPO) traded up 0.73% on Thursday, hitting $40.21. The stock had a trading volume of 2,208 shares. China Biologic Products has a 52 week low of $19.10 and a 52 week high of $41.00. The stock has a 50-day moving average of $37.84 and a 200-day moving average of $32.61. The company has a market cap of $942.6 million and a P/E ratio of 18.90.
China Biologic Products (NASDAQ:CBPO) last released its earnings data on Tuesday, May 6th. The company reported $0.69 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.47 by $0.22. The company had revenue of $56.27 million for the quarter, compared to the consensus estimate of $51.40 million. Analysts expect that China Biologic Products will post $2.49 EPS for the current fiscal year.
China Biologic Products, Inc (NASDAQ:CBPO) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.